Extracellular Vesicle miR-122-5p as a Prognostic Biomarker in Pediatric Classical Hodgkin Lymphoma
Author Information
Author(s): Salzmann Rebekka J. S., Garbin Anna, Gaffo Enrico, Elia Caterina, Martire Gaia, Bortoluzzi Stefania, Tondo Annalisa, Muggeo Paola, Sala Alessandra, Pizzi Marco, Pillon Marta, Carraro Elisa, Lopci Egesta, de Re Valli, Mascarin Maurizio, Mussolin Lara, Poggi Alessandro, Lunavat Taral R.
Primary Institution: Istituto di Ricerca Pediatrica “Città della Speranza”, Padua, Italy
Hypothesis
The study hypothesized that microRNAs could yield comparable prognostic potential in pediatric Hodgkin lymphoma patients.
Conclusion
MiR-122-5p is identified as a strong prognostic biomarker in pediatric classical Hodgkin lymphoma, with higher levels indicating a greater risk of relapse and lower event-free survival.
Supporting Evidence
- MiR-122-5p levels were significantly higher in patients who relapsed compared to those in remission.
- The 5-year event-free survival was significantly different between miR-122 high and low groups.
- MiR-122-5p was associated with clinical events in both univariate and multivariate analyses.
- Elevated levels of CCL17 and IL-6 were found in patients at diagnosis compared to healthy donors.
Takeaway
This study found that a specific molecule in the blood, miR-122-5p, can help doctors predict how well children with a certain type of cancer will do.
Methodology
The study involved small RNA sequencing and RT-qPCR to analyze plasma extracellular vesicles from pediatric classical Hodgkin lymphoma patients.
Limitations
The study primarily reports on miR-122-5p as a new prognostic marker and suggests that further research is needed to explore additional markers and the mechanisms involved.
Participant Demographics
The study included 86 pediatric patients with classical Hodgkin lymphoma.
Statistical Information
P-Value
0.0002
Confidence Interval
65 ± 7% for high levels of miR-122-5p and 93 ± 4% for low levels.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website